靶向CD117的CAR-T细胞在晚期系统性肥大细胞增多症临床前模型中有效清除肥大细胞
本研究评估抗CD117 CAR-T细胞靶向晚期系统性肥大细胞增多症(advSM)肿瘤性肥大细胞(MC)的治疗潜力。体外实验显示抗CD117 CAR-T细胞可有效裂解SM相关人MC细胞系、SM患者来源iPS细胞分化的MC及患者骨髓肿瘤细胞;在免疫缺陷小鼠模型中,重复输注可抑制MC扩增。
要点
- 抗CD117 CAR-T细胞在体外有效裂解SM相关肥大细胞系和患者来源肿瘤细胞。
- 在advSM样MC细胞系移植的免疫缺陷小鼠中,重复给药可抑制MC扩增。
- CD117在MC上的表达高于造血干祖细胞,提示靶向CD117具有治疗价值。
核心结论
- 抗CD117 CAR-T细胞在临床前模型中可有效靶向并清除肿瘤性肥大细胞,为advSM的免疫治疗开发提供了依据。
研究设计与样本
- 临床前研究:体外使用SM相关人MC细胞系、SM患者来源iPS细胞分化的MC及患者骨髓肿瘤细胞;体内使用免疫缺陷小鼠移植advSM样MC细胞系。
主要发现
- 体外,抗CD117-CAR T细胞有效裂解多种SM相关人MC细胞系、SM患者来源iPS细胞分化的MC及SM患者肿瘤性骨髓细胞。
- 在移植advSM样MC细胞系的免疫缺陷小鼠中,重复应用抗CD117-CAR T细胞能够抑制MC扩增。
临床怎么用
- 目前仅为临床前数据,尚不能直接用于临床实践;但支持在advSM中进一步开发抗CD117 CAR-T细胞疗法。
局限性
- 研究限于临床前体外和免疫缺陷小鼠模型,尚未在人体中验证安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic mastocytosis (SM) is characterized by uncontrolled expansion of neoplastic mast cells (MCs) and their accumulation in various tissues and organs, ranging from indolent variants to more advanced forms (advSM). Although several MC- and SM-expressed cell surface antigens have been identified, no immune therapy has been developed for advSM so far. The receptor tyrosine kinase KIT (CD117) is highly expressed on MCs, exceeding the levels of expression on hematopoietic stem and progenitor cells (HSPC). Therefore, targeting CD117 in advSM could be of therapeutic value. In this study, we assessed the therapeutic potential of anti-CD117 chimeric antigen receptor (CAR) T-cells to target neoplastic MCs in SM. In vitro, anti-CD117-CAR T-cells efficiently lysed several SM-related human MC cell lines, MCs differentiated from SM patient-derived induced pluripotent stem (iPS) cells, and neoplastic bone marrow cells obtained from SM patients. Furthermore, in immunocompromised mice engrafted with an advSM-like MC cell line, repetitive applications of anti-CD117-CAR T-cells were able to inhibit MC expansion. These data may pave the way for the development of anti-CD117-CAR T-cell therapies in advSM.
引用
- Kaiser A, Lysenko V, Myburgh R, et al. CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis. Leukemia. 2026. PMID: 42098408. doi:10.1038/s41375-026-02968-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。